TY - JOUR
T1 - Non-castrate metastatic prostate cancer
T2 - Have the treatment options changed?
AU - Palmbos, Phillip L.
AU - Hussain, Maha
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Over the past 7 decades androgen-deprivation therapy (ADT) has been the cornerstone of treatment for metastatic non-castrate prostate cancer (NCPC); however, the mechanisms to achieve this goal have evolved over time to include not only bilateral orchiectomy and estrogens, but also gonadotropin-releasing hormone (GnRH) agonists, antagonists, and the inclusion of androgen receptor (AR) blockade. Despite treatment with ADT, most men will progress to castrate-resistant prostate cancer (CRPC). Over the last decade many new treatment options for CRPC have emerged. These new treatments also could have a meaningful role earlier in NCPC. In this review, we outline the biologic drivers of NCPC, review current standard therapy available for NCPC, and discuss the evolving role of new therapeutics in metastatic disease.
AB - Over the past 7 decades androgen-deprivation therapy (ADT) has been the cornerstone of treatment for metastatic non-castrate prostate cancer (NCPC); however, the mechanisms to achieve this goal have evolved over time to include not only bilateral orchiectomy and estrogens, but also gonadotropin-releasing hormone (GnRH) agonists, antagonists, and the inclusion of androgen receptor (AR) blockade. Despite treatment with ADT, most men will progress to castrate-resistant prostate cancer (CRPC). Over the last decade many new treatment options for CRPC have emerged. These new treatments also could have a meaningful role earlier in NCPC. In this review, we outline the biologic drivers of NCPC, review current standard therapy available for NCPC, and discuss the evolving role of new therapeutics in metastatic disease.
UR - http://www.scopus.com/inward/record.url?scp=84879447404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879447404&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2013.04.007
DO - 10.1053/j.seminoncol.2013.04.007
M3 - Article
C2 - 23806498
AN - SCOPUS:84879447404
VL - 40
SP - 337
EP - 346
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 3
ER -